Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350

PALO ALTO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 34 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 73,700 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranexa is also approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
(Date:10/13/2015)... 2015 Research and Markets( ) has ... Markets for Bone Morphogenetic Protein Growth Factor Therapy - ... --> --> Bone morphogenetic ... of bone after a fracture. In nature, these proteins ... formation of the skeleton. There are twenty different BMPs ...
(Date:10/13/2015)... SAN DIEGO , Oct. 13, 2015 /PRNewswire/ ... agreed to collaborate in the development of a higher ... by BASF under the Kolliphor ® P188 brand, ... and biological applications, such as a shear protectant in ... for Mast,s lead product candidate. Under the agreement between ...
(Date:10/13/2015)... ... October 13, 2015 , ... Exotic ... material handling solutions and components, is opening its latest Parker Store retail location ... facility is Exotic’s second major expansion in Metropolitan Detroit in less than a ...
(Date:10/13/2015)... , October 13, 2015 the United ... Europe .  PRCC represents about 14% of all new cases ... , Canada and Europe ... kidney cancer.   --> Hutchison China MediTech Limited ("Chi-Med") ... R&D subsidiary, and AstraZeneca AB (publ) ("AstraZeneca") have completed enrolment in ...
Breaking Biology Technology:
(Date:9/24/2015)... 24, 2015  EyeLock LLC, a market leader of ... winning and latest technology in Booth #602 at next ... . EyeLock,s iris authentication technology provides an ... accuracy, making it the most proven way to authenticate ... technology to deliver a fast and friendly user experience ...
(Date:9/10/2015)... 2015 Report Details Emerging ... Opportunities and Revenue Prospects to Help You Stay ... especially new drug classes? Get the latest technological ... exclusive market data and industry knowledge, benefitting your ... opportunities and sales predictions. Visiongain,s new study ...
(Date:9/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that the ... Modern, will feature the Wocket® smart wallet for the ... Touch Of Modern is an online ... to its 7.2 million members. Customers are affluent, urban ...
Breaking Biology News(10 mins):